Deb et al. revealed that Akt activation by the epidermal growth factor (EGF) was attenuated upon treatment with PLC inhibitor U-73122, BAPTA-AM, or CaM inhibitor W-7 in c-Myc-overexpressing mammary carcinoma cells [112]. This evidence concerns the gene AKT1 and breast carcinoma.